1
|
Zelencova-Gopejenko D, Andrianov V, Domracheva I, Kanepe-Lapsa I, Milczarek M, Stojak M, Przyborowski K, Fedak FA, Walczak M, Kramkowski K, Wietrzyk J, Chlopicki S, Kalvins I. Aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel PDIA1 and PDIA3 inhibitors. J Enzyme Inhib Med Chem 2023; 38:2158187. [PMID: 37070480 PMCID: PMC10120451 DOI: 10.1080/14756366.2022.2158187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/19/2023] Open
Abstract
In this study, we report a series of newly synthesised sulphonamides of aziridine-2-carboxylic acid (Az-COOH) ester and amide analogues as potent protein disulphide isomerase (PDI, EC 5.3.4.1) inhibitors. The inhibitory activity on PDI was determined against recombinant human PDIA1 and PDIA3 proteins using an insulin reduction assay. These compounds in low micromolar to low nanomolar concentrations showed the effective in vitro inhibitory properties of PDIA1 with weaker effects on PDIA3. Complexes of 15N- and 15N,13C- uniformly labelled recombinant human PDIA1a with two PDIA1 inhibitors were produced and investigated by a protein nuclear magnetic resonance (NMR) spectroscopy. It was found that both C53 and C56 of the PDIA1 enzyme were involved in covalent binding. Finally, in a range of pharmacological studies, we demonstrated that investigated compounds displayed anti-cancer and anti-thrombotic activity. These findings demonstrate that sulphonamides of Az-COOH derivatives are promising candidates for the development of novel anti-cancer and anti-thrombotic agents.
Collapse
Affiliation(s)
- D Zelencova-Gopejenko
- Laboratory of Physical Organic Chemistry, Latvian Institute of Organic Synthesis, Riga, Latvia
| | - V Andrianov
- Laboratory of Carbofunctional Compounds, Latvian Institute of Organic Synthesis, Riga, Latvia
| | - I Domracheva
- Group of Experimental Chemical Therapy, Latvian Institute of Organic Synthesis, Riga, Latvia
| | - I Kanepe-Lapsa
- Group of Experimental Chemical Therapy, Latvian Institute of Organic Synthesis, Riga, Latvia
| | - M Milczarek
- Department of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
| | - M Stojak
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland
| | - K Przyborowski
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland
| | - F A Fedak
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland
| | - M Walczak
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland
- Chair and Department of Toxicology, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland
| | - K Kramkowski
- Department of Physical Chemistry, Medical University of Bialystok, Bialystok, Poland
| | - J Wietrzyk
- Department of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
| | - S Chlopicki
- Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland
- Department of Pharmacology, Jagiellonian University Medical College, Kraków, Poland
| | - I Kalvins
- Laboratory of Carbofunctional Compounds, Latvian Institute of Organic Synthesis, Riga, Latvia
| |
Collapse
|